| Description | This product is a broadly neutralizing antibody, which targeting the receptor-binding domain (RBD) of SARS-CoV-2. The antibody is a rhesus macaque nAb. It has the potent affinity with RBD and it could neutralize against SARS-CoV-2 virus. This product has been tested by Enzyme-linked immunosorbent assay, Bio-layer interferometry and Neutralization assay. |
| Clonality | Monoclonal |
| Host Species | Rhesus macaque |
| Target Species | SARS-CoV-2 |
| Immunogen | SARS-CoV-2 S protein |
| Epitope | Receptor-binding domain (RBD) |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA; BLI; Neut |
| Application Notes | This antibody has been tested by Bio-layer interferometry (BLI) and Neutralization assay. The affinity was tested by BLI, the biosensor was loaded with antigen (His-tagged SARS-CoV-2 RBD protein) and then moved into the antibody at saturating concentration of 100 μg/mL. The neutralizing potency was tested by Neutralization assay, HeLa-hACE2 cells (2 × 105/mL) were suspended and 25 μL of antibody was incubated with 25 μL of pseudovirus at 37°C. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | SARS-CoV-2 S1 |
| Alternative Name | Severe acute respiratory syndrome coronavirus 2 Spike S1 |
| Research Area | Coronavirus Disease 2019 |
| Related Disease | Coronavirus Disease 2019 |
